In Western countries, the number of individuals suffering from an autoimmune condition is constantly growing and often patients suffering from autoimmune disease are susceptible to developing a second autoimmune disorder. We report a case of an adult female patient affected by psoriasis vulgaris and treated with tildrakizumab, a humanized monoclonal antibody targeting interleukin-23, who later developed chronic spontaneous urticaria and started omalizumab, a humanized antibody to IgE, showing a favorable outcome. We speculate that the two combined therapies have restored the cytokine balance bringing it toward tolerance and remission of the two pathologies. It is conceivable that tildrakizumab may have a synergic action with omalizumab in the treatment of urticaria in patients affected by both psoriasis and urticaria. Our case and the study of the mechanisms of action of the two drugs suggest how the two therapies can act with an interlocking mechanism in achieving the final therapeutic effect.

Diluvio, L., Pensa, C., Piccolo, A., Lanna, C., Bianchi, L., Campione, E. (2022). Coesisting inflammatory skin diseases: Tildrakizumab to control psoriasis and omalizumab for urticaria. DERMATOLOGIC THERAPY, 35(4), e15359 [10.1111/dth.15359].

Coesisting inflammatory skin diseases: Tildrakizumab to control psoriasis and omalizumab for urticaria

Bianchi, Luca;Campione, Elena
2022

Abstract

In Western countries, the number of individuals suffering from an autoimmune condition is constantly growing and often patients suffering from autoimmune disease are susceptible to developing a second autoimmune disorder. We report a case of an adult female patient affected by psoriasis vulgaris and treated with tildrakizumab, a humanized monoclonal antibody targeting interleukin-23, who later developed chronic spontaneous urticaria and started omalizumab, a humanized antibody to IgE, showing a favorable outcome. We speculate that the two combined therapies have restored the cytokine balance bringing it toward tolerance and remission of the two pathologies. It is conceivable that tildrakizumab may have a synergic action with omalizumab in the treatment of urticaria in patients affected by both psoriasis and urticaria. Our case and the study of the mechanisms of action of the two drugs suggest how the two therapies can act with an interlocking mechanism in achieving the final therapeutic effect.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35
English
chronic spontaneous urticaria
dual biologic therapy
omalizumab
psoriasis
tildrakizumab
Adult
Antibodies, Monoclonal, Humanized
Chronic Disease
Female
Humans
Omalizumab
Treatment Outcome
Anti-Allergic Agents
Psoriasis
Urticaria
Diluvio, L., Pensa, C., Piccolo, A., Lanna, C., Bianchi, L., Campione, E. (2022). Coesisting inflammatory skin diseases: Tildrakizumab to control psoriasis and omalizumab for urticaria. DERMATOLOGIC THERAPY, 35(4), e15359 [10.1111/dth.15359].
Diluvio, L; Pensa, C; Piccolo, A; Lanna, C; Bianchi, L; Campione, E
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/304595
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact